[Key events from the 4th French-speaking congress on digestive and hepatobiliary surgery: synthesis of the oral communications and report of symposium. December 4-6 2008, Paris].
Are presented in this issue, the main oral communications presented at the 4(th) francophone congress on digestive and hepatobiliary surgery and an overview of the symposium that was dedicated to the metastatic colorectal cancer treatment. Colorectal carcinoma is the second leading cause of cancer in Europe and the third cause of cancer death in the United States. Every year in France, 36,000 new cases are diagnosed, 50% of them with visceral metastases. Among these metastasis patients, 70% exhibit liver metastases exclusively at time of diagnosis. In most patients, liver metastases are non resectable, with exclusive chemotherapy offering poor survival. Surgery is the only curative treatment. Among patients with liver metastases, 10 to 20% are resectable with 40% of them surviving at 5 years. The aim of the chemotherapy intensification schedules is to allow resection in 15 to 30% of initially non resectable metastatic patients and consequently offering some long term survivals. Regarding metastatic colorectal cancer treatment, confrontation between oncologists and surgeons is essential in order to give the opportunity to a significant number of metastatic patients to access to cure.
Goere
D
D
Institut de cancérologie Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif, France.
Mariette
C
C
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery*; D013505:Digestive System Surgical Procedures / Q000379:methods; D006801:Humans; D007391:International Cooperation; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery*; D010297:Paris; D012307:Risk Factors; D012955:Societies, Medical; D016019:Survival Analysis